1-5 of 5
Sheng F. Cai
Close
Sort by
Journal Articles

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML

Clinical Trials & Observations
Sheng F. Cai, Ying Huang, Jennie R. Lance, Hsiaoyin Charlene Mao, Andrew J. Dunbar, Samantha N. McNulty, Todd Druley, Yan Li, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti Patel, Matthew C. Foster, Michael Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy L. Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2024) 8 (2): 429–440.
https://doi.org/10.1182/bloodadvances.2023010563
Published: 2024
Includes: Supplemental data
Journal Articles

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Clinical Trials & Observations
Joseph G. W. McCarter, David Nemirovsky, Christopher A. Famulare, Noushin Farnoud, Abhinita S. Mohanty, Zoe S. Stone-Molloy, Jordan Chervin, Brian J. Ball, Zachary D. Epstein-Peterson, Maria E. Arcila, Aaron J. Stonestrom, Andrew Dunbar, Sheng F. Cai, Jacob L. Glass, Mark B. Geyer, Raajit K. Rampal, Ellin Berman, Omar I. Abdel-Wahab, Eytan M. Stein, Martin S. Tallman, Ross L. Levine, Aaron D. Goldberg, Elli Papaemmanuil, Yanming Zhang, Mikhail Roshal, Andriy Derkach, Wenbin Xiao
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5000–5013.
https://doi.org/10.1182/bloodadvances.2023009675
Published: 2023
Includes: Supplemental data
Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Clinical Trials & Observations
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1552–1564.
https://doi.org/10.1182/bloodadvances.2020003734
Published: 2021
Includes: Supplemental data
Journal Articles

A JAK2 / IDH1 -mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Clinical Trials & Observations
Wenbin Xiao, Linde A. Miles, Robert L. Bowman, Vidushi Durani, Helen S. Tian, Nicole L. DelGaudio, Tanmay Mishra, Menglei Zhu, Yanming Zhang, Sarah E. Stump, Martin S. Tallman, Ross L. Levine, Sheng F. Cai
Journal: Blood Advances
Blood Adv (2020) 4 (23): 6034–6038.
https://doi.org/10.1182/bloodadvances.2020003326
Published: 2020
Journal Articles

Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation

Clinical Trials & Observations
Wenbin Xiao, Mariko Yabe, Michael Offin, Pallavi Khattar, Jeeyeon Baik, Ryan J. Daley, Jeremy J. Pappacena, Mikhail Roshal, Yanming Zhang, Martin S. Tallman, Sheng F. Cai
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1517–1521.
https://doi.org/10.1182/bloodadvances.2018016675
Published: 2018
Includes: Supplemental data